Skip to main content
. Author manuscript; available in PMC: 2014 Nov 18.
Published in final edited form as: J Child Psychol Psychiatry. 2012 Mar 7;53(5):519–535. doi: 10.1111/j.1469-7610.2012.02539.x

Table 1.

Recent Procedures for Diagnosing an Individual as having Alzheimer’s Disorder or not using anatomical MRI data. Two studies used PET imaging data in addition to MRI data. Features extracted from these imaging data typically consisted of voxel-wise maps intensities across the entire brain, therefore yielding a high dimensional feature space. In all studies, the decision boundary within the feature space was learned using support vector machine (SVM), and the classification accuracy was typically assessed using leave-one-out (LOO) cross-validation. SN=sensitivity; SP=specificity; MCI=mild cognitive impairment; MCIc=MCI participants who converted to AD; MCInc=MCI participants who did not convert to AD; GM=gray matter; WM=white matter; CSF=cerebrospinal fluid; ROI=region of interest; PET=positron emission tomography; FDG-PET=18fluorodeoxyglucose-PET; HC=healthy controls; SPHARM=spherical harmonics; SPHARM-PDM=spherical harmonics-point distribution model; LOO=leave-one-out.

Study Participants Features Performance
Fan,
2008(Fan et al., 2008)
56 with AD, 88 with MCI, and 66 healthy
controls
Voxel-wise maps of localized
volumes in (1) GM, (2) WM, and
(3) CSF.
LOO cross-validation.
(1) AD vs HC: Accuracy=94.3%;
(2) MCI vs HC: Accuracy=81.8%;
(3) AD vs MCI: Accuracy=74.3%.
Klöppel,
2008(Klöppel et al., 2008b)
Group 1: 20 with AD and 20 healthy;
Group 2: 14 with AD and 14 healthy. with
histopathological confirmation; and
Group 3: 33 with mild AD and 57 healthy.
Voxel-wise measure of gray
matter intensity
LOO cross-validation.
Group 1: SN=95%; SP=95%;
Group 2: SN=100%; SP=85.7%;
Group 3: SN=60.6%; SP=93%.
Gerardin,
2009(Gerardin et al., 2009)
23 with AD; 23 with MCI; 25 healthy
controls
SPHARM coefficients for the
shape of hippocampus
LOO cross-validation.
(1) AD vs HC: SN=96%;
SP=92%;
(2) MCI vs HC: SN=83%,
SP=84%.
Hinrichs,
2009(Hinrichs et al., 2009)
77 with AD and 82 healthy controls Voxel-wise maps for
(1) gray matter probability, and
(2) FDG-PET intensity
10-fold cross-validation.
SN=78.5%; SP=81.8%.
Magnin,
2009(Magnin et al., 2009)
16 with AD, and 22 healthy controls Percent gray matter within 90
ROIs across the brain.
Bootstrap validation.
SN=91.5%, SP=96.6%.
Misra,
2009(Misra et al., 2009)
103 with MCI who converted to AD
(MCIc); and 76 MCI who did not convert to
AD (MCInc).
Voxel-wise maps of variations in
localized volumes within (1) GM,
(2) WM, and (3) CSF.
LOO cross-validation.
Accuracy (number of correctly
classified) >75%.
Cuingnet,
2011(Cuingnet et al., 2011)
162 elderly controls (HC); 137 with AD; 76
with MCI who converted to AD (MCIc);
134 with MCI who did not convert to AD
(MCInc)
(1) voxel-wise probability maps
of GM, WM, and CSF;
(2) Voxel-wise measure of
cortical thickness;
(3) Hippocampal volume and
shape using spherical armonics
LOO cross-validation.
SN and SP varied across 28
different methods tested:
(1) HC vs AD: SN>63%;
SP>77%. The best SN=81%
and SP=95% (Table 4(Cuingnet et al., 2011));
(2) HC vs MCIc: SN>22%;
SP>73%. The best SN=65%
and SP=94% (Table 5(Cuingnet et al., 2011));
(3) MCInv vs MCIc: SN>0%,
SP>61%. The best SN=57%
and SP=78% (Table 6(Cuingnet et al., 2011)).
Oliveira,
2010(Oliveira et al., 2010)
14 with AD, and 20 healthy controls Volume of 45 brain regions
delineated automatically using
FreeSurfer
LOO cross-validation.
SN=92.8%; SP=85%.
Zhang,
2011(Zhang et al., 2011)
51 with AD, 99 with MCI, and 52 healthy
controls
For 93 ROIs, average measures
of GM volume, and intensity in
PET; and three proteins in CSF.
10-fold cross-validation.
(1) AD vs HC: SN=93%,
SP=93.3%;(2) MCI vs HC: SN=81.8%,
SP=66%.